TY - T1的全球评估肺功能行动(GLI)参考方程扩散能力与呼吸的负担在瑞典心肺BioImage研究(SCAPIS) JF -欧洲呼吸杂志乔-和J欧元做10.1183/13993003.01995 -2019 SP - 1901995 AU Malinovschi安德烈•盟——周室内非盟-烤,Bjorn盟——Bergstrom Goran盟,显得过于安德斯AU -布里斯曼,乔纳斯盟——Caidahl Kenneth AU - Engstrom贡纳AU -埃里克森,玛丽亚j . AU - Frø巫妖,安德烈亚斯AU -詹森,Christer盟——简颂谢尔盟——Vikgren詹妮非盟-林德伯格,安妮AU -林德,罗伯特•AU - Mannila玛丽亚AU -佩尔森,汉斯Lennart AU - Skold教授,C. Magnus AU - Torén, Kjell AU - Östgren, Carl Johan AU - Wollmer, Per AU - Engvall，Jan E. Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/04/01/13993003.01995-2019.abstract N2 -全球肺功能倡议组织(GLI)最近发布了一氧化碳(DLCO)肺扩散能力的国际参考值。正常下限(LLN)，即第5百分位，通常定义DLCO受损。我们研究了DLCO的GLI LLN是否与瑞典健康、不吸烟人群的LLN不同，以及这种差异如何影响对呼吸负担受试者的识别。从瑞典心肺生物图像研究(SCAPIS)的前15040名年龄在50-64岁的参与者中获得肺活量测定、DLCO、胸部高分辨率计算机断层扫描和问卷。使用GLI参考值和lambda-mu-sigma方法来定义无症状不吸烟且无呼吸系统疾病的LLN (n=4903，其中2329名女性)。DLCO的SCAPIS中位数和LLN均高于GLI中位数和LLN (p<0.05)。DLCO <GLI LLN(以及<SCAPIS LLN)的患病率为3.9%，DLCO <SCAPIS LLN和>GLI LLN的患病率分别为5.7%。DLCO >GLI LLN，但<SCAPIS LLN (n=860)比DLCO正常(>LLN GLI和>LLN SCAPIS)的受试者有更多的肺气肿(14.3% vs . 4.5%， p;0.001)、慢性气流限制(8.5% vs . 3.9%， p;0.001)和慢性支气管炎(8.3% vs . 4.4%， p;0.01) (n=13 600)。在医生诊断的哮喘方面没有发现差异。GLI LLN for DLCO is lower than the estimated LLN in Swedish healthy, never-smoking middle-aged adults. Individuals with DLCO above GLI LLN, but below SCAPIS LLN, had to a larger extent an increased respiratory burden. This suggests clinical implications of choosing adequate LLN for studied populations.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Malinovschi has nothing to disclose.Conflict of interest: Dr. Zhou has nothing to disclose.Conflict of interest: Dr. Bake has nothing to disclose.Conflict of interest: Dr. Bergström has nothing to disclose.Conflict of interest: Dr. Blomberg has nothing to disclose.Conflict of interest: Dr. Brisman has nothing to disclose.Conflict of interest: Dr. Caidahl has nothing to disclose.Conflict of interest: Dr. Engström has nothing to disclose.Conflict of interest: Dr. Eriksson has nothing to disclose.Conflict of interest: Dr. Frølich has nothing to disclose.Conflict of interest: Dr. Janson has nothing to disclose.Conflict of interest: Dr. Jansson has nothing to disclose.Conflict of interest: Payment 1-2 lectures annually from Boerhinger -Ingelheim concerning fibrosisConflict of interest: Dr. Lindberg reports personal fees from Boehringer-Ingelheim, personal fees from AstraZeneca, personal fees from Novartis, personal fees from Active Care, outside the submitted work.Conflict of interest: Dr. Linder has nothing to disclose.Conflict of interest: Dr. Mannila has nothing to disclose.Conflict of interest: Dr. Persson has nothing to disclose.Conflict of interest: Dr. Sköld has nothing to disclose.Conflict of interest: Dr. Torén has nothing to disclose.Conflict of interest: Dr. Ostgren has nothing to disclose.Conflict of interest: Dr. Wollmer reports grants from Swedish Heart and Lung Foundation, during the conduct of the study; personal fees from Chiesi Pharma, personal fees from AstraZeneca, outside the submitted work; In addition, Dr. Wollmer has a patent Device and method for pulmonary function measurement issued.Conflict of interest: Dr. Engvall has nothing to disclose. ER -